Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chloroquine in COVID-19 (NO COVID-19)
NCT04316377Phase 4Unknown
- Start
- Mar 2020
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoint: Rate of decline in SARS-CoV-2 viral load at 96 hours. Status: unknown.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04316377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04316377.